Key clinical point: Dupilumab is efficacious and safe in pediatric patients with uncontrolled atopic dermatitis (AD), including those aged 2 to <6 years.
Major finding: At week 16, the mean Eczema Area and Severity Index (EASI) score decreased significantly from 29.0 to 5.1 (P < .0001) and 73.3% and 53.3% of patients achieved ≥75% improvement in EASI and Scoring Atopic Dermatitis scores, respectively. The change in clinical scores was similar among the 2 to <6-year, 6 to <12-year, and 12 to <18-year subgroups. No serious treatment-emergent adverse events were observed.
Study details: This single-center real-world retrospective study included 39 patients aged 2 to <18 years with uncontrolled AD who received dupilumab therapy.
Disclosures: This study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Wang Y et al. Dupilumab improves clinical scores in pediatric patients aged 2 to <18 years with uncontrolled atopic dermatitis: A single-center, real-world study. Dermatol Ther. 2023;5626410 (Apr 17). Doi: 10.1155/2023/5626410